Table 5.
Effect of metformin on life span and tumorigenesis in female 129/Sv mice
| Parameters | Control | Metformin |
|---|---|---|
| Number of mice | 48 | 48 |
| Effective number of mice | 48 | 48 |
| Mean life span, days (M±S.E.M.) | 711± 24.3 | 742 ± 15.8 (+4.4%) |
| Median, days | 715 | 771 (+7.8%) |
| Mean life span of last 10% survivors, days | 910 ± 8.9 | 913 ± 19.2 |
| Maximum life span, days | 945 | 966 |
| α×10−3, days−1 | 7.27 (6.36; 8.20) | 10.40 (8.90;12.50)* |
| MRDT, days | 95 (84;109) | 67 (56; 78)* |
| Number of tumor-bearing mice (%) | 31 (64.6%) | 34 (70.8%) |
| Number of malignant tumor-bearing mice (%) | 7 (15.6%) | 2 (4.2%)* |
| Mean life span of tumor-bearing mice, days | 766 ± 27.3 | 764 ± 18.4 |
| Total number of tumors | 46 | 50 |
| Number of malignant tumors | 9 | 2* |
| Localization and type of tumors | ||
| Uterus: haemangioma & haemangioendotelioma adenocarcinoma sarcoma | 23 2 1 | 30 1 - |
| Ovary: granulesa-cell tumor haemangioma & haemangioendothelioma cystadenoma | 3 7 2 | 1 11 5 |
| Lung: adenoma adenocarcinoma | 2 4 | 1 1 |
| Liver: hepatocellular carcinoma | 1 | - |
| Haematopoietic tissue: leukemia | 1 | - |
Note: Difference with the control is significant:
*
- p<0,005.
α - aging rate; MRDT - mortality rate doubling time, days (in brackets - 95% confidential interval).